Point Biopharma’s closely watched prostate cancer radiopharmaceutical study disappoints, Lilly again extends offer

Point Bio­phar­ma’s ra­dio­phar­ma­ceu­ti­cal prostate can­cer treat­ment staved off dis­ease pro­gres­sion or death by 3.5 months com­pared to hor­mone ther­a­py in a close­ly watched Phase III tri­al.

How­ev­er, an­a­lysts said the re­sults dis­ap­point­ed com­pared to a sim­i­lar ther­a­py from No­var­tis. The da­ta come at a piv­otal time for the com­pa­ny, with share­hold­ers hold­ing out against an ac­qui­si­tion of­fer from Eli Lil­ly in hopes of a bet­ter deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.